Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.41 |
| ▸ | MMP12 | P39900 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MMP14 | P50281 | 6/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75900 | 1.00 | MMP13 (0.41) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL2967822 | 1.00 | MMP13 (0.41) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| Hydantoin SCHEMBL5243531 | 0.86 | MMP13 (0.37) | MMP13MMP12MMP14KCNH2 | |
| SCHEMBL2967748 | 0.81 | SMN1; SMN2 (0.43) | MMP13MMP12SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL2970475 | 0.80 | MMP13 (0.39) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL2970478 | 0.80 | MMP13 (0.39) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL3457549 | 0.78 | ALDH1A1 (0.47) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL1363544 | 0.74 | SMN1; SMN2 (0.42) | MMP13MMP12SMN1; SMN2NPSR1MMP14 | |
| SCHEMBL73830 | 0.73 | LMNA (0.38) | ALDH1A1ADAMTS5 | |
| SCHEMBL2963931 | 0.73 | LMNA (0.38) | ALDH1A1ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1676846-B1 | Hydantoin derivatives as MMP inhibitors | ASTRAZENECA AB (SE) | 2010-12-29 | — | — | EP | claimed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | claimed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | claimed |
| US-8153673-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8129412-B2 | Hydantoin derivatives useful as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-1831199-B1 | MMP inhibitors | ASTRAZENECA AB (SE) | 2012-02-15 | — | — | EP | disclosed |
| US-7989620-B2 | Hydantoin derivatives for the treatment of obstructive airway diseases | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| EP-1676846-B1 | Hydantoin derivatives as MMP inhibitors | ASTRAZENECA AB (SE) | 2010-12-29 | — | — | EP | disclosed |
| CN-1509286-A | Metalloprotease inhibitors | — | 2004-06-30 | — | — | CN | disclosed |
| WO-2004024718-A1 | IMIDAZOLIDINEDIONE-DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004024698-A1 | 1-SULPHONYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370537-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074751-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP13 12/4885MMP12 2/4885SMN1; SMN2 2584/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP13 12/4885MMP12 2/4885SMN1; SMN2 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.